President Obama’s final State of the Union address could not have set a better tone for the year ahead for the innovator biopharmaceutical industry.
The direct impact of any State of the Union address is limited at best, and the importance of an eighth...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?